RECOVER试验:迷走神经刺激治疗高度难治性抑郁症的关键发现与启示
本综述总结RECOVER试验,该12个月三盲随机对照试验纳入493例高度难治性抑郁症成人,比较辅助活性与假迷走神经刺激。预设主要终点未达显著,但多个症状、功能与生活质量指标显著偏向活性刺激;第二年继续治疗显示获益持久。
要点
- 预设主要终点未区分组间,但多个次要终点显著偏向活性VNS。
- 12个月有效者在18和24个月时超过80%维持获益。
- 约30%的12个月无获益者在第二年出现有意义改善。
核心结论
- 在高度难治性抑郁症中,辅助活性VNS在多个指标上优于假刺激,持续治疗与获益持久相关。
研究设计与样本
- RECOVER为12个月三盲随机试验,纳入493例当前发作至少4种治疗失败的成人重性抑郁障碍患者,比较辅助活性与假VNS。
- 参与者平均终生抗抑郁治疗13.3种,当前发作持续时间17.8年。
- 第二年评估活性VNS获益的持久性。
主要发现
- 预设主要终点(MADRS应答时间百分比)未区分治疗组。
- QIDS-C应答率活性组39.6% vs 假组30.7%;CGI改善53.8% vs 39.8%。
- WPAI第6项改善43.3% vs 37.5%;Q-LES-Q-7改善45.4% vs 37.1%。
- 12个月时有意义获益者中超过80%在18和24个月时维持获益。
- 约30%的12个月无获益者在第二年出现有意义改善。
关键数值与推荐
- 预设主要终点为MADRS应答时间百分比,未达显著组间差异。
- QIDS-C应答率活性组39.6% vs 假组30.7%。
- CGI改善率活性组53.8% vs 假组39.8%。
- WPAI第6项改善率活性组43.3% vs 假组37.5%。
- Q-LES-Q-7改善率活性组45.4% vs 假组37.1%。
临床怎么用
- 对高度难治性抑郁症患者,辅助VNS可作为多指标获益的考虑选项。
- 治疗决策应关注症状、功能和生活质量等多维度结局。
- 持续VNS治疗可能带来持久获益,需长期随访评估。
局限性
- 预设主要终点未达显著,结论基于多个次要终点。
- 样本为高度难治性人群,结果外推需谨慎。
- 综述讨论了评估高度难治性抑郁结局的挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This review summarizes the RECOVER trial's key findings and their clinical and research implications. RECOVER was a 12-month triple-blind randomized trial in adults with markedly treatment-resistant major depressive disorder (N=493; at least four failed trials in the current episode) that compared adjunctive active and sham vagus nerve stimulation (VNS) in effects on symptoms, function, and quality of life (QoL). Durability of benefit during the second year of active VNS was also evaluated. Participants had profoundly treatment-resistant illness, averaging 13.3 lifetime antidepressant treatments and a duration of 17.8 years for the current episode. The prespecified primary outcome (percent time in Montgomery-Åsberg Depression Rating Scale response) did not differentiate the treatment groups, while other outcomes for symptoms (Quick Inventory of Depressive Symptomatology-Clinician Rated: 39.6% vs. 30.7%; Clinical Global Impressions improvement scale: 53.8% vs. 39.8%), function (item 6 on the Work Productivity and Activity Impairment Questionnaire: 43.3% vs. 37.5%), and QoL (7-item subset of the Quality of Life Enjoyment and Satisfaction Questionnaire: 45.4% vs. 37.1%) and a tripartite metric combining these three outcome domains significantly favored active stimulation. Over 80% of participants who achieved meaningful benefit in symptom, function, or QoL measures after 12 months of active VNS retained these benefits at the 18- and 24-month assessments, demonstrating remarkable durability in participants expected to relapse at high rates. Approximately 30% of participants without benefit at 12 months improved meaningfully in the second year. In markedly treatment-resistant depression, adjunctive active VNS was more effective, in multiple measures, than a sham intervention administered over the course of 1 year. Continued treatment with active VNS was associated with durable improvement. Challenges and optimal methods for evaluating outcomes in samples with markedly treatment-resistant depression are discussed.
引用
- Conway CR, Sackeim HA, Rush AJ, et al. The RECOVER Trial of Vagus Nerve Stimulation in Markedly Treatment-Resistant Depression: Critical Findings, Lessons Learned, and Future Directions. Am J Psychiatry. 2026. PMID: 42642808. doi:10.1176/appi.ajp.20251339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。